eli lilly oral glp 1 Orforglipron: Lilly's New GLP-1 Weight-loss Pill Founday (orforglipron), the new oral

This is significant because current lupus nephritis management relies heavily on immunosuppressants (mycophenolate, cyclophosphamide, voclosporin) and biologics (belimumab, rituximab)

Key references include the Stark et al

GLP-1s also interact with receptors in your brain and brainstem that regulate food intake and energy use

However, these agents increase risk of intra-operative pulmonary aspiration according to a case report secondary to delayed emptying and presence of gastric residues despite fasting (108, 108) To prevent these events, the recent recommendations from the American Society of Anesthesiology guidelines suggest discontinuing GLP-1 receptor agonists 1 day prior in patients on daily dosing and 1 week prior in patients on weekly injection dosing (108)